Laurie Gaspar, MD, Professor and Chair Department of Radiation Oncology, Grohne Chair in Clinical Oncology, University of Colorado School of Medicine, discusses the risk of pneumonitis from radiation among patients with lung cancer.
Laurie Gaspar, MD, Professor and Chair Department of Radiation Oncology, Grohne Chair in Clinical Oncology, University of Colorado School of Medicine, discusses the risk of pneumonitis from radiation among patients with lung cancer.
Some large cooperative group studies claim that the risk of symptomatic radiation pneumonitis is small -- less than 10%. On an actuarial basis, Gaspar says, about 30-40% of patients experience pneumonitis at 1 year.Gaspar says this larger figure needs to be discussed with patients and physicians need to work on lowering the percentage. Most oncologists also agree that some side effects from radiation are being underestimated, Gaspar says
Phase 3 CheckMate -73L of Nivolumab/Ipilimumab in NSCLC Misses PFS End Point
May 13th 2024Nivolumab with ipilimumab did not lead to progression-free survival benefits in patients with unresectable stage III non-small cell lung cancer, missing the primary end point of the CheckMate -73L study.
Read More